Last reviewed · How we verify
Switch ritonavir-boosted PI
A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load.
A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load. Used for HIV-1 infection (as part of antiretroviral therapy).
At a glance
| Generic name | Switch ritonavir-boosted PI |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Protease inhibitor (boosted) |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ritonavir-boosted protease inhibitor (PI) regimens combine a primary protease inhibitor with ritonavir, a potent CYP3A4 inhibitor that increases the plasma concentration and half-life of the primary PI. This pharmacokinetic boosting allows for lower doses and less frequent dosing of the primary protease inhibitor while maintaining therapeutic efficacy against HIV protease, which is essential for viral maturation and infectivity.
Approved indications
- HIV-1 infection (as part of antiretroviral therapy)
Common side effects
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Lipid abnormalities (elevated cholesterol and triglycerides)
- Hyperglycemia
- Hepatotoxicity
- Lipodystrophy
Key clinical trials
- Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance (PHASE3)
- Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels (PHASE4)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
- Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (PHASE4)
- Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection (PHASE2)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (PHASE3)
- MARCH Central Nervous System Substudy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Switch ritonavir-boosted PI CI brief — competitive landscape report
- Switch ritonavir-boosted PI updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI